206 related articles for article (PubMed ID: 6383851)
1. Short-term of the artificial beta-cell (Biostator) on pancreatic glucagon response in insulin-dependent diabetic (IDDM).
Ratzmann KP; Schneider U; Besch W; Heinke P
Exp Clin Endocrinol; 1984 Jul; 84(1):91-8. PubMed ID: 6383851
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and hormonal responses during a glucose controlled insulin infusion (Biostator) in subjects with impaired glucose tolerance.
Ratzmann KP; Schneider U; Peters U; Ziegler M; Schulz B
Exp Clin Endocrinol; 1984 May; 83(3):334-42. PubMed ID: 6381073
[TBL] [Abstract][Full Text] [Related]
3. The metabolic and hormonal response to acute normoglycaemia in type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas).
Nosadini R; Noy GA; Nattrass M; Alberti KG; Johnston DG; Home PD; Orskov H
Diabetologia; 1982 Sep; 23(3):220-8. PubMed ID: 6751902
[TBL] [Abstract][Full Text] [Related]
4. The ketosis-resistance in fibro-calculous-pancreatic-diabetes. 1. Clinical observations and endocrine-metabolic measurements during oral glucose tolerance test.
Yajnik CS; Shelgikar KM; Naik SS; Kanitkar SV; Orskov H; Alberti KG; Hockaday TD
Diabetes Res Clin Pract; 1992 Feb; 15(2):149-56. PubMed ID: 1563331
[TBL] [Abstract][Full Text] [Related]
5. Islet hormonal regulation of glucose turnover during exercise in type 1 diabetes.
Shilo S; Sotsky M; Shamoon H
J Clin Endocrinol Metab; 1990 Jan; 70(1):162-72. PubMed ID: 1967178
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
[TBL] [Abstract][Full Text] [Related]
7. Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans.
Berk MA; Clutter WE; Skor D; Shah SD; Gingerich RP; Parvin CA; Cryer PE
J Clin Invest; 1985 Jun; 75(6):1842-51. PubMed ID: 3891786
[TBL] [Abstract][Full Text] [Related]
8. Improvement in blunted glucagon response to insulin-induced hypoglycemia by strict glycemic control in diabetics.
Katsura M; Kawamori R; Yamasaki Y; Iwama N; Kubota M; Goriya Y; Kajimoto Y; Shichiri M; Kamada T
Diabetes Res Clin Pract; 1993 May; 20(2):93-100. PubMed ID: 8375272
[TBL] [Abstract][Full Text] [Related]
9. Hormonal and metabolic responses in brittle diabetic patients during feedback intravenous insulin infusion.
Massi Benedetti M; Home PD; Gill GV; Burrin JM; Noy GA; Alberti KG
Diabetes Res Clin Pract; 1987; 3(6):307-17. PubMed ID: 3311678
[TBL] [Abstract][Full Text] [Related]
10. Reversal of D- and A-cell insensitivity to glucose in alloxan-diabetic dogs by treatment with the artificial beta cell (Biostator).
Hermansen K; Schmitz O; Orskov H
Diabetes; 1985 Mar; 34(3):260-6. PubMed ID: 2857668
[TBL] [Abstract][Full Text] [Related]
11. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics.
Schock A; Schultz M; Kerner W; Maier V; Pfeiffer EF
Horm Metab Res Suppl; 1979; (8):93-6. PubMed ID: 395097
[TBL] [Abstract][Full Text] [Related]
12. Glucagon responses to intravenous arginine and oral glucose in insulin-dependent diabetic patients during six months conventional or continuous subcutaneous insulin infusion.
Hermansen K; Schmitz O; Boye N; Christensen CK; Christiansen JS; Alberti KG; Orskov H; Mogensen CE
Metabolism; 1988 Jul; 37(7):640-4. PubMed ID: 3290622
[TBL] [Abstract][Full Text] [Related]
13. [Blood glucose, C-peptide and glucagon levels in patients with a labile course of diabetes mellitus during use of the device "Biostator"].
Spesivtseva VG; Turova EA; Mamaeva GG; Sotnikova TI
Probl Endokrinol (Mosk); 1985; 31(5):63-7. PubMed ID: 4070196
[TBL] [Abstract][Full Text] [Related]
14. Hyperglycemia after intense exercise in IDDM subjects during continuous subcutaneous insulin infusion.
Mitchell TH; Abraham G; Schiffrin A; Leiter LA; Marliss EB
Diabetes Care; 1988 Apr; 11(4):311-7. PubMed ID: 3042306
[TBL] [Abstract][Full Text] [Related]
15. Near normalization of metabolism of IDDM: comparison of continuous subcutaneous (CSII) versus intraperitoneal (CIPII) insulin delivery.
Gooch BR; Abumrad NN; Robinson RP; Crofford OB
Horm Metab Res; 1984 Dec; 16 Suppl 1():190-4. PubMed ID: 6398261
[TBL] [Abstract][Full Text] [Related]
16. Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes.
Ratzmann KP; Schulz B; Heinke P; Besch W
Diabetologia; 1984 Jul; 27(1):8-12. PubMed ID: 6147291
[TBL] [Abstract][Full Text] [Related]
17. Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy.
Del Prato S; Tiengo A; Baccaglini U; Tremolada C; Duner E; Marescotti MC; Avogaro A; Valverde I; Nosadini R; Assan R
Diabetologia; 1983 Sep; 25(3):252-9. PubMed ID: 6357912
[TBL] [Abstract][Full Text] [Related]
18. Insulin clearance contributes to the variability of nocturnal insulin requirement in insulin-dependent diabetes mellitus.
Dux S; White NH; Skor DA; Santiago JV
Diabetes; 1985 Dec; 34(12):1260-5. PubMed ID: 3905459
[TBL] [Abstract][Full Text] [Related]
19. Clinical forms and natural history of the diabetic syndrome and insulin and glucagon secretion in the BB rat.
Marliss EB; Nakhooda AF; Poussier P
Metabolism; 1983 Jul; 32(7 Suppl 1):11-7. PubMed ID: 6345995
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of exaggerated glucagon response to arginine in diabetes mellitus.
Kawamori R; Shichiri M; Kikuchi M; Yamasaki Y; Abe H
Diabetes Res Clin Pract; 1985 Oct; 1(3):131-7. PubMed ID: 3915260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
